Roche sues Stanford University, cancer-detection startup over trade secrets
By Blake Brittain
July 2 (Reuters) -Roche ROG.S has sued Stanford University and medical technology startup Foresight Diagnostics in California federal court, claiming Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products.
Roche said in the complaint filed on Monday that Stanford University professors Maximilian Diehn and Ash Alizadeh, whose technology Roche acquired in 2015, secretly created Foresight while working as Roche consultants and stole its technology to use in their new business.
Spokespeople for Foresight and Roche declined to comment on the lawsuit on Tuesday. Spokespeople for Stanford did not immediately respond to requests for comment.
According to the complaint, Roche bought Diehn and Alizadeh's Capp Medical in 2015 along with its technology for analyzing DNA from a patient's bloodstream to detect cancer. Roche said that it paid "tens of millions of dollars" for the technology and uses it in its Avenio cancer-detection kits.
The lawsuit said that Diehn, Alizadeh and fellow Stanford professor David Kurtz worked for Roche when they founded Boulder, Colorado-based Foresight in 2020. The complaint accused Foresight of misusing the technology that Roche acquired to raise more than $70 million in funding for its own cancer-detection business.
Roche requested an unspecified amount of money damages and also asked the court to force Stanford and Foresight to hand over patent applications that allegedly cover Roche's technology.
The case is Roche Molecular Systems Inc v. Foresight Diagnostics Inc, U.S. District Court for the Northern District of California, No. 5:24-cv-03972.
For Roche: Mark Flanagan, Robert Gunther and Christopher Noyes of Wilmer Cutler Pickering Hale & Dorr
For Foresight and Stanford: attorney information not yet available
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
